BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALK202 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALK202\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06707610-2341@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ALK202: Phase 1 readout est. (NCT06707610)
DESCRIPTION:ALK202\, phase 1.\nStudy: A Study to Evaluate the Safety\, Tole
 rability\, Pharmacokinetics (PK)\, and Antitumor Activity of ALK202 in Par
 ticipants with Advanced Solid Tumors\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/alk202#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06707610
URL:https://assetmemo.bio/drug/alk202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-2341@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ALK202: Phase 2 readout est. (NCT07603791)
DESCRIPTION:ALK202\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II
  Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics a
 nd Antitumor Activity of ALK202 for Injection in Combination With Drugs in
  NSCLC Participants.\nEstimated primary completion: 30 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/alk202#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07603791
URL:https://assetmemo.bio/drug/alk202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
